Following an announcement of a critical milestone in the commercialization of its flagship technology, Profound Medical Corp. (NASDAQ: PROF) shares saw notable rises on Tuesday. During regular trading, PROF stock rose 17.39% to conclude at $6.75, while after-hours trading saw a further 5.78% climb to $7.14.
Breakthrough Milestone
The rally came in response to the announcement that the first commercial patient had been treated using the company’s advanced TULSA-AI Volume Reduction Module, designed for benign prostatic hyperplasia (BPH).
Profound Medical verified that Dr. Naveen Kella of The Urology Place in San Antonio successfully completed the first commercial TULSA treatment utilizing the AI-based module. Lower urinary tract symptoms (LUTS), which are frequently caused by benign prostatic hyperplasia (BPH), have a substantial negative impact on quality of life.
Conventional therapies, such as transurethral resection of the prostate (TURP), have not evolved much in a century and are linked to concerns including erectile dysfunction, bleeding, and extensive recovery periods.
Innovative, AI-Driven Procedure
The TULSA-PRO system, now enhanced by the TULSA-AI Volume Reduction Module, offers a minimally invasive, incision-free solution that preserves urinary and sexual function while reducing obstructive prostate tissue.
Utilizing real-time MRI and artificial intelligence, the procedure tailors treatment based on each patient’s unique anatomy. The new module optimizes treatment planning and ablation precision, reducing total procedure time to 60–90 minutes and eliminating the need for hospital stays.
Market Expansion and Clinical Impact
With this technological advancement, Profound Medical is poised to significantly expand its market reach. Moreover, clinical findings, including data from the University of Turku, highlight improvements in patient outcomes such as symptom relief, urinary flow, and medication discontinuation—positioning TULSA-AI as a potential game-changer in prostate care.
The TULSA-AI enhancement aims to address the previous barrier of longer procedure times for BPH-only patients. Now, Profound Medical projects an increase in its annual market opportunity from 200,000 to 600,000 treatable cases.
